金吾财讯 | 诺和诺德(NVO)公布了CagriSema临床数据,在REDEFINE 4试验中展现出23%的减重效果,但研究未达到预设的主要目标。在临床试验中,公司的卡格列肽(Cagrisema)效果未能达到不劣于礼来的替尔泊肽(Tirzepatide)的疗效标准。
金吾财讯 | 诺和诺德(NVO)公布了CagriSema临床数据,在REDEFINE 4试验中展现出23%的减重效果,但研究未达到预设的主要目标。在临床试验中,公司的卡格列肽(Cagrisema)效果未能达到不劣于礼来的替尔泊肽(Tirzepatide)的疗效标准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.